** Chimeric Therapeutics CHM.AX falls 7.7% to A$0.006, lowest since February 26
** Biotech firm says it intends to raise up to A$3.2 mln ($1.99 mln) at A$0.005, a discount of 28.6% to last close
** Adds funds will used for continued development of co's CDH17 Phase 1/2 clinical trial
** Stock down 14.3% YTD
($1 = A$1.6116)
(Reporting by Kumar Tanishk in Bengaluru)
((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。